{
"info": {
"nct_id": "NCT04235101",
"official_title": "A Two-part Phase I Study With the Antibody-drug Conjugate SYD985 in Combination With Niraparib to Evaluate Safety, Pharmacokinetics and Efficacy in Patients With HER2-expressing Locally Advanced or Metastatic Solid Tumors.",
"inclusion_criteria": "* Male or female, age ≥ 18 years at the time of signing first informed consent;\n* Patient with a histologically-confirmed, locally advanced or metastatic tumour who has progressed on standard therapy or for whom no standard therapy exists, with the following restriction:\n\n * Part 1: solid tumours of any origin;\n * Part 2: breast cancer, ovarian cancer or endometrial carcinoma/carcinosarcoma;\n* HER2 tumor status at least 1+ as assessed by immunohistochemistry (IHC) as determined by the local laboratory;\n* Presence of a tumor lesion accessible for biopsy and patient should be willing to undergo a fresh biopsy for central HER2 testing and genetic testing, unless adequate (biopsy) tumour material is available obtained < 6 months prior to signing the main informed consent;\n* At least one measurable cancer lesion as defined by the Response Evaluation Criteria for Solid Tumours (RECIST version 1.1);\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1;\n* Adequate organ function.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Having been treated with:\n\n 1. DUBA-containing ADCs at any time;\n 2. Anthracycline treatment within 8 weeks prior to start of study treatment;\n 3. Other anticancer therapy including chemotherapy, immunotherapy, or investigational agents within 4 weeks prior to start of study treatment or 5 times the half-life of the therapy, whichever is shorter;\n 4. Radiotherapy within 4 weeks prior to start of study treatment or within 1 week for palliative care (as long as the lungs were not exposed);\n 5. Hormone therapy within 1 week prior to start of study treatment. The patient must have sufficiently recovered from any treatment-related toxicities to NCI CTCAE Grade ≤ 1 (except for toxicities not considered a safety risk for the patient at the investigator's discretion);\n* History or presence of keratitis;\n* Left ventricular ejection fraction (LVEF) < 50% as assessed by either echocardiography or multigated acquisition (MUGA) scan at screening, or a history of clinically significant decrease in LVEF during previous trastuzumab containing treatment leading to permanent discontinuation of treatment;\n* History (within 6 months prior to start of study treatment) or presence of clinically significant cardiovascular disease such as unstable angina, congestive heart failure, myocardial infarction, uncontrolled hypertension, or cardiac arrhythmia requiring medication;\n* History or presence of idiopathic pulmonary fibrosis, organizing pneumonia (e.g. bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan;\n* Severe, uncontrolled systemic disease (e.g. clinically significant cardiovascular, pulmonary, or metabolic disease) at screening;\n* Symptomatic brain metastases, brain metastasis requiring steroids to manage symptoms or treatment for brain metastases within 8 weeks prior to start of study treatment.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"identified_line": {
"line": "* Patient with a histologically-confirmed, locally advanced or metastatic tumour who has progressed on standard therapy or for whom no standard therapy exists, with the following restriction:",
"criterions": [
{
"exact_snippets": "histologically-confirmed, locally advanced or metastatic tumour",
"criterion": "tumour status",
"requirement": {
"requirement_type": "confirmation",
"expected_value": "histologically-confirmed"
}
},
{
"exact_snippets": "histologically-confirmed, locally advanced or metastatic tumour",
"criterion": "tumour status",
"requirement": {
"requirement_type": "stage",
"expected_value": [
"locally advanced",
"metastatic"
]
}
},
{
"exact_snippets": "progressed on standard therapy",
"criterion": "progression on standard therapy",
"requirement": {
"requirement_type": "progression",
"expected_value": true
}
},
{
"exact_snippets": "for whom no standard therapy exists",
"criterion": "availability of standard therapy",
"requirement": {
"requirement_type": "availability",
"expected_value": false
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "histologically-confirmed, locally advanced or metastatic tumour",
"criterion": "tumour status",
"requirement": {
"requirement_type": "confirmation",
"expected_value": "histologically-confirmed"
}
},
{
"exact_snippets": "histologically-confirmed, locally advanced or metastatic tumour",
"criterion": "tumour status",
"requirement": {
"requirement_type": "stage",
"expected_value": [
"locally advanced",
"metastatic"
]
}
}
]
},
{
"or_criteria": [
{
"exact_snippets": "progressed on standard therapy",
"criterion": "progression on standard therapy",
"requirement": {
"requirement_type": "progression",
"expected_value": true
}
},
{
"exact_snippets": "for whom no standard therapy exists",
"criterion": "availability of standard therapy",
"requirement": {
"requirement_type": "availability",
"expected_value": false
}
}
]
}
]
}
]
}
},
{
"identified_line": {
"line": "* Part 1: solid tumours of any origin;",
"criterions": [
{
"exact_snippets": "solid tumours of any origin",
"criterion": "solid tumours",
"requirement": {
"requirement_type": "origin",
"expected_value": "any"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "solid tumours of any origin",
"criterion": "solid tumours",
"requirement": {
"requirement_type": "origin",
"expected_value": "any"
}
}
]
}
},
{
"identified_line": {
"line": "* Part 2: breast cancer, ovarian cancer or endometrial carcinoma/carcinosarcoma;",
"criterions": [
{
"exact_snippets": "breast cancer",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "ovarian cancer",
"criterion": "ovarian cancer",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "endometrial carcinoma/carcinosarcoma",
"criterion": "endometrial carcinoma/carcinosarcoma",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "breast cancer",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "ovarian cancer",
"criterion": "ovarian cancer",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "endometrial carcinoma/carcinosarcoma",
"criterion": "endometrial carcinoma/carcinosarcoma",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* HER2 tumor status at least 1+ as assessed by immunohistochemistry (IHC) as determined by the local laboratory;",
"criterions": [
{
"exact_snippets": "HER2 tumor status at least 1+ ... as assessed by immunohistochemistry (IHC)",
"criterion": "HER2 tumor status",
"requirement": {
"requirement_type": "assessment method",
"expected_value": "immunohistochemistry (IHC)"
}
},
{
"exact_snippets": "HER2 tumor status at least 1+ ... as assessed by immunohistochemistry (IHC)",
"criterion": "HER2 tumor status",
"requirement": {
"requirement_type": "value",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "+"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "HER2 tumor status at least 1+ ... as assessed by immunohistochemistry (IHC)",
"criterion": "HER2 tumor status",
"requirement": {
"requirement_type": "assessment method",
"expected_value": "immunohistochemistry (IHC)"
}
},
{
"exact_snippets": "HER2 tumor status at least 1+ ... as assessed by immunohistochemistry (IHC)",
"criterion": "HER2 tumor status",
"requirement": {
"requirement_type": "value",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "+"
}
}
}
]
}
},
{
"identified_line": {
"line": "* Presence of a tumor lesion accessible for biopsy and patient should be willing to undergo a fresh biopsy for central HER2 testing and genetic testing, unless adequate (biopsy) tumour material is available obtained < 6 months prior to signing the main informed consent;",
"criterions": [
{
"exact_snippets": "Presence of a tumor lesion accessible for biopsy",
"criterion": "tumor lesion",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Presence of a tumor lesion accessible for biopsy",
"criterion": "tumor lesion",
"requirement": {
"requirement_type": "accessibility for biopsy",
"expected_value": true
}
},
{
"exact_snippets": "patient should be willing to undergo a fresh biopsy",
"criterion": "willingness to undergo fresh biopsy",
"requirement": {
"requirement_type": "willingness",
"expected_value": true
}
},
{
"exact_snippets": "adequate (biopsy) tumour material is available obtained < 6 months prior to signing the main informed consent",
"criterion": "biopsy tumour material",
"requirement": {
"requirement_type": "availability",
"expected_value": true
}
},
{
"exact_snippets": "adequate (biopsy) tumour material is available obtained < 6 months prior to signing the main informed consent",
"criterion": "biopsy tumour material",
"requirement": {
"requirement_type": "recency",
"expected_value": {
"operator": "<",
"value": 6,
"unit": "months"
}
}
}
]
},
"logical_structure": {
"condition": {
"and_criteria": [
{
"and_criteria": [
{
"and_criteria": [
{
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Presence of a tumor lesion accessible for biopsy",
"criterion": "tumor lesion",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Presence of a tumor lesion accessible for biopsy",
"criterion": "tumor lesion",
"requirement": {
"requirement_type": "accessibility for biopsy",
"expected_value": true
}
}
]
},
{
"exact_snippets": "patient should be willing to undergo a fresh biopsy",
"criterion": "willingness to undergo fresh biopsy",
"requirement": {
"requirement_type": "willingness",
"expected_value": true
}
}
]
}
]
}
]
}
]
},
"then_criteria": null,
"else_criteria": {
"and_criteria": [
{
"exact_snippets": "adequate (biopsy) tumour material is available obtained < 6 months prior to signing the main informed consent",
"criterion": "biopsy tumour material",
"requirement": {
"requirement_type": "availability",
"expected_value": true
}
},
{
"exact_snippets": "adequate (biopsy) tumour material is available obtained < 6 months prior to signing the main informed consent",
"criterion": "biopsy tumour material",
"requirement": {
"requirement_type": "recency",
"expected_value": {
"operator": "<",
"value": 6,
"unit": "months"
}
}
}
]
}
}
},
{
"identified_line": {
"line": "* At least one measurable cancer lesion as defined by the Response Evaluation Criteria for Solid Tumours (RECIST version 1.1);",
"criterions": [
{
"exact_snippets": "At least one measurable cancer lesion",
"criterion": "measurable cancer lesion",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "lesion"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "At least one measurable cancer lesion",
"criterion": "measurable cancer lesion",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "lesion"
}
}
}
]
}
},
{
"identified_line": {
"line": "* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1;",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1",
"criterion": "ECOG performance status",
"requirement": {
"requirement_type": "performance status",
"expected_value": {
"operator": "<=",
"value": 1,
"unit": "N/A"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1",
"criterion": "ECOG performance status",
"requirement": {
"requirement_type": "performance status",
"expected_value": {
"operator": "<=",
"value": 1,
"unit": "N/A"
}
}
}
]
}
},
{
"identified_line": {
"line": "* Adequate organ function.",
"criterions": [
{
"exact_snippets": "Adequate organ function",
"criterion": "organ function",
"requirement": {
"requirement_type": "adequacy",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Adequate organ function",
"criterion": "organ function",
"requirement": {
"requirement_type": "adequacy",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
}
},
{
"identified_line": {
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
}
}
],
"exclusion_lines": [
{
"identified_line": {
"line": "* Having been treated with:",
"criterions": [
{
"exact_snippets": "Having been treated with",
"criterion": "prior treatment",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Having been treated with",
"criterion": "prior treatment",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "1. DUBA-containing ADCs at any time;",
"criterions": [
{
"exact_snippets": "DUBA-containing ADCs at any time",
"criterion": "DUBA-containing ADCs",
"requirement": {
"requirement_type": "exposure",
"expected_value": false
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "DUBA-containing ADCs at any time",
"criterion": "DUBA-containing ADCs",
"requirement": {
"requirement_type": "exposure",
"expected_value": false
}
}
}
},
{
"identified_line": {
"line": "2. Anthracycline treatment within 8 weeks prior to start of study treatment;",
"criterions": [
{
"exact_snippets": "Anthracycline treatment within 8 weeks prior to start of study treatment",
"criterion": "anthracycline treatment",
"requirement": {
"requirement_type": "time frame",
"expected_value": {
"operator": "<=",
"value": 8,
"unit": "weeks"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Anthracycline treatment within 8 weeks prior to start of study treatment",
"criterion": "anthracycline treatment",
"requirement": {
"requirement_type": "time frame",
"expected_value": {
"operator": "<=",
"value": 8,
"unit": "weeks"
}
}
}
]
}
},
{
"identified_line": {
"line": "4. Radiotherapy within 4 weeks prior to start of study treatment or within 1 week for palliative care (as long as the lungs were not exposed);",
"criterions": [
{
"exact_snippets": "Radiotherapy within 4 weeks prior to start of study treatment",
"criterion": "radiotherapy",
"requirement": {
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
},
{
"exact_snippets": "Radiotherapy ... within 1 week for palliative care (as long as the lungs were not exposed)",
"criterion": "radiotherapy for palliative care",
"requirement": {
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "week"
}
}
},
{
"exact_snippets": "Radiotherapy ... within 1 week for palliative care (as long as the lungs were not exposed)",
"criterion": "radiotherapy for palliative care",
"requirement": {
"requirement_type": "lung exposure",
"expected_value": false
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Radiotherapy within 4 weeks prior to start of study treatment",
"criterion": "radiotherapy",
"requirement": {
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "Radiotherapy ... within 1 week for palliative care (as long as the lungs were not exposed)",
"criterion": "radiotherapy for palliative care",
"requirement": {
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "week"
}
}
},
{
"exact_snippets": "Radiotherapy ... within 1 week for palliative care (as long as the lungs were not exposed)",
"criterion": "radiotherapy for palliative care",
"requirement": {
"requirement_type": "lung exposure",
"expected_value": false
}
}
]
}
]
}
]
}
},
{
"identified_line": {
"line": "5. Hormone therapy within 1 week prior to start of study treatment. The patient must have sufficiently recovered from any treatment-related toxicities to NCI CTCAE Grade ≤ 1 (except for toxicities not considered a safety risk for the patient at the investigator's discretion);",
"criterions": [
{
"exact_snippets": "Hormone therapy within 1 week prior to start of study treatment",
"criterion": "hormone therapy",
"requirement": {
"requirement_type": "time since last treatment",
"expected_value": {
"operator": "<=",
"value": 1,
"unit": "week"
}
}
},
{
"exact_snippets": "sufficiently recovered from any treatment-related toxicities to NCI CTCAE Grade ≤ 1",
"criterion": "treatment-related toxicities",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": "<=",
"value": 1,
"unit": "NCI CTCAE Grade"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"not_criteria": {
"and_criteria": [
{
"exact_snippets": "Hormone therapy within 1 week prior to start of study treatment",
"criterion": "hormone therapy",
"requirement": {
"requirement_type": "time since last treatment",
"expected_value": {
"operator": "<=",
"value": 1,
"unit": "week"
}
}
},
{
"exact_snippets": "sufficiently recovered from any treatment-related toxicities to NCI CTCAE Grade ≤ 1",
"criterion": "treatment-related toxicities",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": "<=",
"value": 1,
"unit": "NCI CTCAE Grade"
}
}
}
]
}
}
]
}
},
{
"identified_line": {
"line": "* History or presence of keratitis;",
"criterions": [
{
"exact_snippets": "History or presence of keratitis",
"criterion": "keratitis",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "History or presence of keratitis",
"criterion": "keratitis",
"requirement": {
"requirement_type": "history",
"expected_value": true
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "History or presence of keratitis",
"criterion": "keratitis",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "History or presence of keratitis",
"criterion": "keratitis",
"requirement": {
"requirement_type": "history",
"expected_value": true
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Left ventricular ejection fraction (LVEF) < 50% as assessed by either echocardiography or multigated acquisition (MUGA) scan at screening, or a history of clinically significant decrease in LVEF during previous trastuzumab containing treatment leading to permanent discontinuation of treatment;",
"criterions": [
{
"exact_snippets": "Left ventricular ejection fraction (LVEF) < 50%",
"criterion": "left ventricular ejection fraction (LVEF)",
"requirement": {
"requirement_type": "value",
"expected_value": {
"operator": "<",
"value": 50,
"unit": "%"
}
}
},
{
"exact_snippets": "history of clinically significant decrease in LVEF during previous trastuzumab containing treatment leading to permanent discontinuation of treatment",
"criterion": "history of clinically significant decrease in LVEF",
"requirement": {
"requirement_type": "treatment impact",
"expected_value": "permanent discontinuation of trastuzumab containing treatment"
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Left ventricular ejection fraction (LVEF) < 50%",
"criterion": "left ventricular ejection fraction (LVEF)",
"requirement": {
"requirement_type": "value",
"expected_value": {
"operator": "<",
"value": 50,
"unit": "%"
}
}
},
{
"or_criteria": [
{
"exact_snippets": "assessed by either echocardiography",
"criterion": "assessment method",
"requirement": {
"requirement_type": "method",
"expected_value": "echocardiography"
}
},
{
"exact_snippets": "assessed by ... multigated acquisition (MUGA) scan",
"criterion": "assessment method",
"requirement": {
"requirement_type": "method",
"expected_value": "multigated acquisition (MUGA) scan"
}
}
]
}
]
},
{
"exact_snippets": "history of clinically significant decrease in LVEF during previous trastuzumab containing treatment leading to permanent discontinuation of treatment",
"criterion": "history of clinically significant decrease in LVEF",
"requirement": {
"requirement_type": "treatment impact",
"expected_value": "permanent discontinuation of trastuzumab containing treatment"
}
}
]
}
},
{
"identified_line": {
"line": "* History (within 6 months prior to start of study treatment) or presence of clinically significant cardiovascular disease such as unstable angina, congestive heart failure, myocardial infarction, uncontrolled hypertension, or cardiac arrhythmia requiring medication;",
"criterions": [
{
"exact_snippets": "History (within 6 months prior to start of study treatment) or presence of clinically significant cardiovascular disease such as unstable angina",
"criterion": "unstable angina",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "History (within 6 months prior to start of study treatment) or presence of clinically significant cardiovascular disease such as ... congestive heart failure",
"criterion": "congestive heart failure",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "History (within 6 months prior to start of study treatment) or presence of clinically significant cardiovascular disease such as ... myocardial infarction",
"criterion": "myocardial infarction",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "History (within 6 months prior to start of study treatment) or presence of clinically significant cardiovascular disease such as ... uncontrolled hypertension",
"criterion": "uncontrolled hypertension",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "History (within 6 months prior to start of study treatment) or presence of clinically significant cardiovascular disease such as ... cardiac arrhythmia requiring medication",
"criterion": "cardiac arrhythmia",
"requirement": {
"requirement_type": "medication requirement",
"expected_value": true
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "History (within 6 months prior to start of study treatment) or presence of clinically significant cardiovascular disease such as unstable angina",
"criterion": "unstable angina",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "History (within 6 months prior to start of study treatment) or presence of clinically significant cardiovascular disease such as ... congestive heart failure",
"criterion": "congestive heart failure",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "History (within 6 months prior to start of study treatment) or presence of clinically significant cardiovascular disease such as ... myocardial infarction",
"criterion": "myocardial infarction",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "History (within 6 months prior to start of study treatment) or presence of clinically significant cardiovascular disease such as ... uncontrolled hypertension",
"criterion": "uncontrolled hypertension",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "History (within 6 months prior to start of study treatment) or presence of clinically significant cardiovascular disease such as ... cardiac arrhythmia requiring medication",
"criterion": "cardiac arrhythmia",
"requirement": {
"requirement_type": "medication requirement",
"expected_value": true
}
}
]
}
]
},
{
"or_criteria": [
{
"exact_snippets": "History (within 6 months prior to start of study treatment) or presence of clinically significant cardiovascular disease such as unstable angina",
"criterion": "unstable angina",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "History (within 6 months prior to start of study treatment) or presence of clinically significant cardiovascular disease such as ... congestive heart failure",
"criterion": "congestive heart failure",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "History (within 6 months prior to start of study treatment) or presence of clinically significant cardiovascular disease such as ... myocardial infarction",
"criterion": "myocardial infarction",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "History (within 6 months prior to start of study treatment) or presence of clinically significant cardiovascular disease such as ... uncontrolled hypertension",
"criterion": "uncontrolled hypertension",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "History (within 6 months prior to start of study treatment) or presence of clinically significant cardiovascular disease such as ... cardiac arrhythmia requiring medication",
"criterion": "cardiac arrhythmia",
"requirement": {
"requirement_type": "medication requirement",
"expected_value": true
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Severe, uncontrolled systemic disease (e.g. clinically significant cardiovascular, pulmonary, or metabolic disease) at screening;",
"criterions": [
{
"exact_snippets": "Severe, uncontrolled systemic disease",
"criterion": "systemic disease",
"requirement": {
"requirement_type": "severity",
"expected_value": "severe"
}
},
{
"exact_snippets": "Severe, uncontrolled systemic disease",
"criterion": "systemic disease",
"requirement": {
"requirement_type": "control",
"expected_value": false
}
},
{
"exact_snippets": "clinically significant cardiovascular ... disease",
"criterion": "cardiovascular disease",
"requirement": {
"requirement_type": "clinical significance",
"expected_value": true
}
},
{
"exact_snippets": "clinically significant ... pulmonary ... disease",
"criterion": "pulmonary disease",
"requirement": {
"requirement_type": "clinical significance",
"expected_value": true
}
},
{
"exact_snippets": "clinically significant ... metabolic disease",
"criterion": "metabolic disease",
"requirement": {
"requirement_type": "clinical significance",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Severe, uncontrolled systemic disease",
"criterion": "systemic disease",
"requirement": {
"requirement_type": "severity",
"expected_value": "severe"
}
},
{
"exact_snippets": "Severe, uncontrolled systemic disease",
"criterion": "systemic disease",
"requirement": {
"requirement_type": "control",
"expected_value": false
}
}
]
},
{
"or_criteria": [
{
"exact_snippets": "clinically significant cardiovascular ... disease",
"criterion": "cardiovascular disease",
"requirement": {
"requirement_type": "clinical significance",
"expected_value": true
}
},
{
"exact_snippets": "clinically significant ... pulmonary ... disease",
"criterion": "pulmonary disease",
"requirement": {
"requirement_type": "clinical significance",
"expected_value": true
}
},
{
"exact_snippets": "clinically significant ... metabolic disease",
"criterion": "metabolic disease",
"requirement": {
"requirement_type": "clinical significance",
"expected_value": true
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Symptomatic brain metastases, brain metastasis requiring steroids to manage symptoms or treatment for brain metastases within 8 weeks prior to start of study treatment.",
"criterions": [
{
"exact_snippets": "Symptomatic brain metastases",
"criterion": "brain metastases",
"requirement": {
"requirement_type": "symptomatic",
"expected_value": true
}
},
{
"exact_snippets": "brain metastasis requiring steroids to manage symptoms",
"criterion": "brain metastases",
"requirement": {
"requirement_type": "steroid requirement",
"expected_value": true
}
},
{
"exact_snippets": "treatment for brain metastases within 8 weeks prior to start of study treatment",
"criterion": "brain metastases",
"requirement": {
"requirement_type": "treatment timing",
"expected_value": {
"operator": "<=",
"value": 8,
"unit": "weeks"
}
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Symptomatic brain metastases",
"criterion": "brain metastases",
"requirement": {
"requirement_type": "symptomatic",
"expected_value": true
}
},
{
"exact_snippets": "brain metastasis requiring steroids to manage symptoms",
"criterion": "brain metastases",
"requirement": {
"requirement_type": "steroid requirement",
"expected_value": true
}
},
{
"exact_snippets": "treatment for brain metastases within 8 weeks prior to start of study treatment",
"criterion": "brain metastases",
"requirement": {
"requirement_type": "treatment timing",
"expected_value": {
"operator": "<=",
"value": 8,
"unit": "weeks"
}
}
}
]
}
}
],
"miscellaneous_lines": [],
"failed_inclusion": [
{
"identified_line": {
"line": "* Male or female, age ≥ 18 years at the time of signing first informed consent;",
"criterions": [
{
"exact_snippets": "Male or female",
"criterion": "gender",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "age ≥ 18 years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Male or female",
"criterion": "gender",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"and_criteria": [
{
"exact_snippets": "age \u001e 18 years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
}
]
}
]
}
}
],
"failed_exclusion": [
{
"identified_line": {
"line": "3. Other anticancer therapy including chemotherapy, immunotherapy, or investigational agents within 4 weeks prior to start of study treatment or 5 times the half-life of the therapy, whichever is shorter;",
"criterions": [
{
"exact_snippets": "Other anticancer therapy including chemotherapy, immunotherapy, or investigational agents",
"criterion": "anticancer therapy",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "within 4 weeks prior to start of study treatment or 5 times the half-life of the therapy, whichever is shorter",
"criterion": "time since last anticancer therapy",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 4,
"unit": "weeks"
}
]
}
}
},
{
"exact_snippets": "within 4 weeks prior to start of study treatment or 5 times the half-life of the therapy, whichever is shorter",
"criterion": "time since last anticancer therapy",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 5,
"unit": "times the half-life of the therapy"
}
]
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Other anticancer therapy including chemotherapy, immunotherapy, or investigational agents",
"criterion": "anticancer therapy",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"or_criteria": [
{
"exact_snippets": "within 4 weeks prior to start of study treatment or 5 times the half-life of the therapy, whichever is shorter",
"criterion": "time since last anticancer therapy",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 4,
"unit": "weeks"
}
]
}
}
},
{
"exact_snippets": "within 4 weeks prior to start of study treatment or 5 times the half-life of the therapy, whichever is shorter",
"criterion": "time since last anticancer therapy",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 5,
"unit": "times the half-life of the therapy"
}
]
}
}
}
]
}
]
}
]
}
},
{
"identified_line": {
"line": "* History or presence of idiopathic pulmonary fibrosis, organizing pneumonia (e.g. bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan;",
"criterions": [
{
"exact_snippets": "History or presence of idiopathic pulmonary fibrosis",
"criterion": "idiopathic pulmonary fibrosis",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "History or presence of ... organizing pneumonia (e.g. bronchiolitis obliterans)",
"criterion": "organizing pneumonia",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "History or presence of ... drug-induced pneumonitis",
"criterion": "drug-induced pneumonitis",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "History or presence of ... idiopathic pneumonitis",
"criterion": "idiopathic pneumonitis",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "evidence of active pneumonitis on screening chest CT scan",
"criterion": "active pneumonitis",
"requirement": {
"requirement_type": "evidence",
"expected_value": true
}
}
]
},
"logical_structure": {
"exact_snippets": "failed",
"criterion": "failed",
"requirement": {
"requirement_type": "failed",
"expected_value": "failed"
}
}
}
],
"failed_miscellaneous": []
}